Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Deloitte
Federal Trade Commission
Queensland Health
Merck
Cantor Fitzgerald
Cerilliant
Mallinckrodt
Dow
Moodys

Generated: August 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Methods and compositions for the treatment of gastrointestinal disorders
Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s): Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Norman; Thea (San Diego, CA), Milne; G. Todd (Brookline, MA)
Assignee: Ironwood Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:11/930,696
Patent Claims: 1. A polypeptide comprising the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr wherein Xaa is selected from Phe, Trp or Tyr (SEQ ID NO: 125) or a pharmaceutically acceptable salt thereof.

2. The polypeptide of claim 1 consisting of the amino acid sequence Cys Cys Glu Xaa Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr wherein Xaa is selected from Phe, Trp or Tyr (SEQ ID NO:125).

3. The polypeptide according to claim 1, which is purified.

4. The polypeptide according to claim 2, which is purified.

5. The polypeptide of claim 1 comprising the amino acid sequence Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 105) or a pharmaceutically acceptable salt thereof.

6. The polypeptide of claim 5 consisting of the amino acid sequence Cys Cys Glu Phe Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO:105).

7. The polypeptide of claim 5 or a pharmaceutically acceptable salt thereof, wherein the polypeptide activates the guanylate cyclase C receptor.

8. A pharmaceutical composition comprising the polypeptide of claim 5 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

9. The polypeptide of claim 1 comprising the amino acid sequence Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 109) or a pharmaceutically acceptable salt thereof.

10. The polypeptide of claim 9 consisting of the amino acid sequence Cys Cys Glu Trp Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (SEQ ID NO: 109).

11. The polypeptide of claim 9 or a pharmaceutically acceptable salt thereof, wherein the polypeptide activates the guanylate cyclase C receptor.

12. A pharmaceutical composition comprising the polypeptide of claim 9 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

13. A pharmaceutical composition comprising the polypeptide of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

14. A pharmaceutical composition comprising the polypeptide of claim 2 and a pharmaceutically acceptable carrier or excipient.

15. A pharmaceutical composition comprising the polypeptide of claim 6 and a pharmaceutically acceptable carrier or excipient.

16. A pharmaceutical composition comprising the polypeptide of claim 10 and a pharmaceutically acceptable carrier or excipient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
McKesson
US Department of Justice
Fish and Richardson
Mallinckrodt
Cantor Fitzgerald
Colorcon
Daiichi Sankyo
McKinsey
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot